Clinical Trial Update: Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support [Phase 3]

View source ↗

Summary

Novartis completed a Phase 3 trial evaluating how inclisiran is delivered in primary care with enhanced support, focusing on implementation outcomes in ASCVD an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Leqvio (inclisiran) (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents | Phase 3 | Status: COMPLETED | Results posted: 2024-03-25